Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 3
2013 2
2014 9
2015 19
2016 53
2017 61
2018 84
2019 68
2020 64
2021 62
2022 35
2023 13
2024 7
2025 6
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

415 results

Results by year

Filters applied: . Clear all
Page 1
Elbasvir-grazoprevir: A new direct-acting antiviral combination for hepatitis C.
Karaoui LR, Mansour H, Chahine EB. Karaoui LR, et al. Am J Health Syst Pharm. 2017 Oct 1;74(19):1533-1540. doi: 10.2146/ajhp160558. Am J Health Syst Pharm. 2017. PMID: 28947524 Review.
Elbasvir exhibits antiviral activity against HCV genotypes 1a, 1b, 2a, 3a, and 4a. Elbasvir-grazoprevir undergoes fecal excretion, does not require dosage adjustment in patients with renal impairment, and is contraindicated in moderate and severe hepatic impairment. …
Elbasvir exhibits antiviral activity against HCV genotypes 1a, 1b, 2a, 3a, and 4a. Elbasvir-grazoprevir undergoes fecal excret …
Zepatier.
[No authors listed] [No authors listed] 2022 Feb 7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2022 Feb 7. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644238 Free Books & Documents. Review.
Zepatier is an oral, fixed combination of two antiviral agents, elbasvir and grazoprevir, that is used to treat chronic hepatitis C, genotypes 1 and 4. ...However, like all effective direct acting antiviral agents for hepatitis C, Zepatier is co …
Zepatier is an oral, fixed combination of two antiviral agents, elbasvir and grazoprevir, that is used to treat chronic …
Protease Inhibitors (HCV).
[No authors listed] [No authors listed] 2022 Jan 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2022 Jan 25. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644194 Free Books & Documents. Review.
The combination of an HCV protease inhibitor with other antiviral agents with activity against HCV (such as peginterferon, ribavirin, and the direct acting agents that block the NS5A and NS5B regions of the virus) leads to marked decrease in HCV replication a …
The combination of an HCV protease inhibitor with other antiviral agents with activity against HCV (such as peginterferon, rib …
Direct anti-HCV agents.
Zhang X. Zhang X. Acta Pharm Sin B. 2016 Jan;6(1):26-31. doi: 10.1016/j.apsb.2015.09.008. Epub 2015 Nov 24. Acta Pharm Sin B. 2016. PMID: 26904396 Free PMC article. Review.
Unlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus (HCV) infection is a curable disease. Current direct antiviral agent (DAA) targets are focused on HCV NS3/4A protein (protease), NS5B protein (polymerase) and NS5A protein. ...The inve …
Unlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus (HCV) infection is a curable disease. Current direc …
Amino Acid and Peptide-Based Antiviral Agents.
Skwarecki AS, Nowak MG, Milewska MJ. Skwarecki AS, et al. ChemMedChem. 2021 Oct 15;16(20):3106-3135. doi: 10.1002/cmdc.202100397. Epub 2021 Aug 3. ChemMedChem. 2021. PMID: 34254457 Review.
A significant number of antiviral agents used in clinical practice are amino acids, short peptides, or peptidomimetics. ...Herein, we present a concise review of antiviral agents whose structures are based on amino acids of both natural and unnatural o …
A significant number of antiviral agents used in clinical practice are amino acids, short peptides, or peptidomimetics. ...Her …
Grazoprevir/elbasvir combination therapy for HCV infection.
Vallet-Pichard A, Pol S. Vallet-Pichard A, et al. Ther Adv Gastroenterol. 2017 Jan;10(1):155-167. doi: 10.1177/1756283X16671293. Epub 2016 Oct 17. Ther Adv Gastroenterol. 2017. PMID: 28286567 Free PMC article. Review.
Interferon-free regimens combine different second-wave direct-acting antiviral agents (DAAs), which target the main viral proteins involved in the replication cycle of hepatitis C virus (HCV): NS3/4A protease inhibitors (simeprevir or paritaprevir boosted by ritonav …
Interferon-free regimens combine different second-wave direct-acting antiviral agents (DAAs), which target the main viral prot …
Dual therapy of grazoprevir and elbasvir for the treatment of hepatitis C infection.
Landaverde C, Wells J, Hamner R, Goldstein JL. Landaverde C, et al. Expert Rev Gastroenterol Hepatol. 2016;10(4):419-29. doi: 10.1586/17474124.2016.1147346. Epub 2016 Feb 24. Expert Rev Gastroenterol Hepatol. 2016. PMID: 26818134 Review.
The development of interferon-free regimens involving the use of direct-acting antiviral agents, which disrupt key steps in viral replication, has revolutionized the treatment of chronic HCV infection. However, there remains a great medical need for HCV therapy that …
The development of interferon-free regimens involving the use of direct-acting antiviral agents, which disrupt key steps in vi …
Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3.
Yeh WW, Fraser IP, Jumes P, Petry A, Lepeleire I, Robberechts M, Reitmann C, Van Dyck K, Huang X, Guo Z, Panebianco D, Nachbar RB, O'Mara E, Wagner JA, Butterton JR, Dutko FJ, Moiseev V, Kobalava Z, Hüser A, Visan S, Schwabe C, Gane E, Popa S, Ghicavii N, Uhle M, Wagner F. Yeh WW, et al. Clin Ther. 2018 May;40(5):704-718.e6. doi: 10.1016/j.clinthera.2018.03.002. Epub 2018 Apr 25. Clin Ther. 2018. PMID: 29703432 Clinical Trial.
The aims of these studies were to evaluate the antiviral activity and safety of different doses of elbasvir or grazoprevir each administered as monotherapy to participants infected with either HCV genotype (GT) 1 or GT3. METHODS: These 2 double-blind, randomized, pl …
The aims of these studies were to evaluate the antiviral activity and safety of different doses of elbasvir or grazoprevir eac …
Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4.
El Kassas M, Elbaz T, Abd El Latif Y, Esmat G. El Kassas M, et al. Expert Rev Clin Pharmacol. 2016 Nov;9(11):1413-1421. doi: 10.1080/17512433.2016.1233813. Epub 2016 Sep 26. Expert Rev Clin Pharmacol. 2016. PMID: 27603877 Review.
During the last few years, treatment of hepatitis C virus (HCV) revolutionized with the appearance of direct antiviral agents especially for patients with HCV genotypes 1 and 4 infections. Elbasvir (NS5A inhibitor) and grazoprevir (NS3/4A protease inhibitor) …
During the last few years, treatment of hepatitis C virus (HCV) revolutionized with the appearance of direct antiviral agents …
415 results